Mural Oncology to Present at Two Upcoming Investor Conferences
2024年8月27日 - 8:00PM
Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology
company developing novel, investigational engineered cytokine
therapies designed to address areas of unmet need for patients with
a variety of cancers, today announced that members of its
management team will participate at two upcoming investor
conferences and take 1x1 meetings. A webcast of both presentations
will be available at ir.muraloncology.com.
Morgan Stanley
22nd Annual Global Healthcare
Conference
Fireside chat with Caroline Loew, Ph.D., CEO, Vicki Goodman, MD,
Chief Medical Officer, and Adam Cutler, Chief Financial Officer
Date: Friday, September 6
Time: 1:50 p.m. ET
H.C. Wainwright 26th
Annual Global Investment Conference
Presentation by Caroline Loew, Ph.D.
Date: Wednesday, September 11
Time: 9:30 a.m. ET
About Mural Oncology
Mural Oncology is leveraging its novel protein engineering
platform to develop cytokine-based immunotherapies for the
treatment of cancer. By combining our expertise in cytokine biology
and immune cell modulation and our protein engineering platform, we
are developing medicines to deliver meaningful and clinical
benefits to people living with cancer. Our mission is to
broaden the potential and reach of cytokine-based immunotherapies
to improve the lives of patients. Our lead candidate, nemvaleukin,
is currently in potentially registrational trials in mucosal
melanoma and platinum-resistant ovarian cancer. Mural Oncology has
its registered office in Dublin, Ireland, and its primary
facilities in Waltham, Mass. For more information, visit Mural
Oncology’s website at www.muraloncology.com and follow us on
LinkedIn and X.
ContactKatie
Sullivankatie.sullivan@muraloncology.com
Mural Oncology (NASDAQ:MURA)
過去 株価チャート
から 8 2024 まで 9 2024
Mural Oncology (NASDAQ:MURA)
過去 株価チャート
から 9 2023 まで 9 2024